MacroGenics (NASDAQ:MGNX – Get Free Report) and Insulet (NASDAQ:PODD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.
Valuation and Earnings
This table compares MacroGenics and Insulet”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MacroGenics | $149.50 million | 1.86 | -$74.62 million | ($1.10) | -3.98 |
| Insulet | $2.71 billion | 3.73 | $247.10 million | $4.30 | 33.96 |
Insider & Institutional Ownership
96.9% of MacroGenics shares are held by institutional investors. 13.6% of MacroGenics shares are held by company insiders. Comparatively, 0.4% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares MacroGenics and Insulet’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MacroGenics | -44.79% | -147.80% | -28.40% |
| Insulet | 10.44% | 26.87% | 12.01% |
Risk & Volatility
MacroGenics has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Insulet has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations for MacroGenics and Insulet, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MacroGenics | 1 | 3 | 3 | 0 | 2.29 |
| Insulet | 1 | 5 | 21 | 0 | 2.74 |
MacroGenics currently has a consensus price target of $5.50, indicating a potential upside of 25.57%. Insulet has a consensus price target of $252.48, indicating a potential upside of 72.92%. Given Insulet’s stronger consensus rating and higher possible upside, analysts clearly believe Insulet is more favorable than MacroGenics.
Summary
Insulet beats MacroGenics on 12 of the 14 factors compared between the two stocks.
About MacroGenics
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
About Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.
